Publication

OHDSI Global | Poster | Enhancing Cardiovascular Adverse Event Detection in ICI-Treated Cancer Patients: Lessons Learned from Natural Language Processing Integration with OMOP CDM

Cardiovascular (CV) adverse events (AEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) are often under-detected in clinical trials, partly due to the strict inclusion criteria and limited follow-up typical of such studies. This underscores the need for real-world data analysis to gain a fuller understanding of these events.

Download our joint poster (as showcased at the OHDSI Global 2024 conference) by completing the form.

Authors: Clara L. Oeste1, Danielle Delombaerde2, Annelies Verbiest3, Iege Bassez1, Philip Debruyne4, Christof Vulsteke2, Dries Hens1

Oncology

In this Publication you’ll learn:

In this article you’ll learn:

Background

• Cardiovascular (CV) adverse events (AEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) are often under-detected in clinical trials.

• Clinical trials typically have strict inclusion criteria and incomplete follow-up, highlighting the need for real-world data analysis.

• This study used both structured data and NLP-extracted unstructured EHR data.

• The integration of NLP with structured data enriched the OMOP CDM, presenting an important analytic use case for the OHDSI community.

Conclusion

• NLP enhances the detection of CV AEs in ICI-treated cancer patients, particularly for less common events like pericarditis (78%) and myocarditis (60%).

• The combination of NLP and structured data improves AE identification, with NLP contributing 32-78% of additional cases across various categories.

• High precision, recall, and F1 scores validate the accuracy of NLP, enabling more comprehensive follow-up and monitoring in oncology care.

Complete the form above to download the poster and discover the methods used and the results obtained.

Click HERE to visit our Oncology Insights overview for more information on the LynxCare datasets within our European hospital network.

1 LynxCare, Leuven, Belgium
2 Department of Oncology, General Hospital AZ Maria Middelares, Ghent, Belgium and Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
3 Department of Oncology Antwerp University Hospital, Antwerp, Belgium
4 Department of Medical Oncology, General Hospital AZ Groeninge, Kortrijk, Belgium

Background

• Cardiovascular (CV) adverse events (AEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) are often under-detected in clinical trials.

• Clinical trials typically have strict inclusion criteria and incomplete follow-up, highlighting the need for real-world data analysis.

• This study used both structured data and NLP-extracted unstructured EHR data.

• The integration of NLP with structured data enriched the OMOP CDM, presenting an important analytic use case for the OHDSI community.

Conclusion

• NLP enhances the detection of CV AEs in ICI-treated cancer patients, particularly for less common events like pericarditis (78%) and myocarditis (60%).

• The combination of NLP and structured data improves AE identification, with NLP contributing 32-78% of additional cases across various categories.

• High precision, recall, and F1 scores validate the accuracy of NLP, enabling more comprehensive follow-up and monitoring in oncology care.

Complete the form above to download the poster and discover the methods used and the results obtained.

Click HERE to visit our Oncology Insights overview for more information on the LynxCare datasets within our European hospital network.

1 LynxCare, Leuven, Belgium
2 Department of Oncology, General Hospital AZ Maria Middelares, Ghent, Belgium and Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium
3 Department of Oncology Antwerp University Hospital, Antwerp, Belgium
4 Department of Medical Oncology, General Hospital AZ Groeninge, Kortrijk, Belgium

Publication

OHDSI Global | Poster | Enhancing Cardiovascular Adverse Event Detection in ICI-Treated Cancer Patients: Lessons Learned from Natural Language Processing Integration with OMOP CDM

Cardiovascular (CV) adverse events (AEs) in cancer patients receiving immune checkpoint inhibitors (ICIs) are often under-detected in clinical trials, partly due to the strict inclusion criteria and limited follow-up typical of such studies. This underscores the need for real-world data analysis to gain a fuller understanding of these events.

Download our joint poster (as showcased at the OHDSI Global 2024 conference) by completing the form.

Authors: Clara L. Oeste1, Danielle Delombaerde2, Annelies Verbiest3, Iege Bassez1, Philip Debruyne4, Christof Vulsteke2, Dries Hens1

DOWNLOAD
DOWNLOAD
Talk to an Expert

Cardiovascular adverse events in cancer patients receiving immune checkpoint inhibitors are often under-detected in clinical trials, partly due to the strict inclusion criteria and limited follow-up typical of such studies. This underscores the need for real-world data analysis to gain a more comprehensive understanding of these events.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.